<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To obtain data on efficacy, safety and tolerability of <z:chebi fb="0" ids="2376">acarbose</z:chebi> monotherapy or combination therapy during daily-life treatment </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This prospective, non-controlled, observational study enrolled patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, whose physician decided that <z:chebi fb="0" ids="2376">acarbose</z:chebi> treatment was appropriate, from China, Middle East, Indonesia, Morocco, Pakistan, Philippines, Poland and Taiwan </plain></SENT>
<SENT sid="2" pm="."><plain>The observation period included an initial visit and up to three follow-up visits; an extension of 2 years was realized in Pakistan and Poland </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Of 14,574 patients enrolled, 14,418 comprised the intent-to-treat population </plain></SENT>
<SENT sid="4" pm="."><plain>At the initial visit, 74.1% of patients had been treated with a <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering agent </plain></SENT>
<SENT sid="5" pm="."><plain>Fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> was reduced from 175.2mg/dL at the initial visit to 133.7 mg/dL at the last visit (mean of 11.3 weeks after initial visit; P&lt;0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>Mean 2-h postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> decreased from 244.7 mg/dL to 172.4 mg/dL (P&lt;0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>HbA1c reduced from 8.4% to 7.4% (P&lt;0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>Glycemic efficacy was maintained over the 2-year extension period </plain></SENT>
<SENT sid="9" pm="."><plain>There were 432 adverse events in 293 patients (2.03%), mainly gastrointestinal </plain></SENT>
<SENT sid="10" pm="."><plain>Physicians assessed efficacy as "very good"/"good" in 85.1% of patients, and were "very satisfied"/"satisfied" with <z:chebi fb="0" ids="2376">acarbose</z:chebi> therapy in 94.3% of cases </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="2376">Acarbose</z:chebi> therapy was efficacious and well tolerated in daily life in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>